全系统使用精准肿瘤学作为标准护理范例所面临的挑战和解决方案。

Cambridge prisms, Precision medicine Pub Date : 2024-03-26 eCollection Date: 2024-01-01 DOI:10.1017/pcm.2024.1
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, Andrew Haworth, Kerrie Woods, Charles Crichton, Theresa Noble, Hizni Salih, Kinga A Várnai, Harriet Branford-White, Liam Orrell, Andrew Osman, Kevin M Bradley, Lara Bonney, Daniel R McGowan, Jim Davies, Matthew S Prime, Andrew Bassim Hassan
{"title":"全系统使用精准肿瘤学作为标准护理范例所面临的挑战和解决方案。","authors":"Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, Andrew Haworth, Kerrie Woods, Charles Crichton, Theresa Noble, Hizni Salih, Kinga A Várnai, Harriet Branford-White, Liam Orrell, Andrew Osman, Kevin M Bradley, Lara Bonney, Daniel R McGowan, Jim Davies, Matthew S Prime, Andrew Bassim Hassan","doi":"10.1017/pcm.2024.1","DOIUrl":null,"url":null,"abstract":"<p><p>The personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the 'molecular tumour board' into 'standard of care' ensures a unified clinical decision pathway that both counteracts fragmentation and is the cornerstone of evidence-based delivery inside and outside of a research setting. Generally, integrated delivery has been restricted to specific (common) cancer types either within major cancer centres or small regional networks. Here, we focus on solutions in real-world integration of genomics, pathology, surgery, oncological treatments, data from clinical source systems and analysis of whole-body imaging as digital data that can facilitate cost-effectiveness analysis, clinical trial recruitment, and outcome assessment. This urgent imperative for cancer also extends across the early diagnosis and adjuvant treatment interventions, individualised cancer vaccines, immune cell therapies, personalised synthetic lethal therapeutics and cancer screening and prevention. Oncology care systems worldwide require proactive step-changes in solutions that include inter-operative digital working that can solve patient centred challenges to ensure inclusive, quality, sustainable, fair and cost-effective adoption and efficient delivery. Here we highlight workforce, technical, clinical, regulatory and economic challenges that prevent the implementation of precision oncology at scale, and offer a systematic roadmap of integrated solutions for standard of care based on minimal essential digital tools. These include unified decision support tools, quality control, data flows within an ethical and legal data framework, training and certification, monitoring and feedback. Bridging the technical, operational, regulatory and economic gaps demands the joint actions from public and industry stakeholders across national and global boundaries.</p>","PeriodicalId":72491,"journal":{"name":"Cambridge prisms, Precision medicine","volume":"2 ","pages":"e4"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062796/pdf/","citationCount":"0","resultStr":"{\"title\":\"Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm.\",\"authors\":\"Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, Andrew Haworth, Kerrie Woods, Charles Crichton, Theresa Noble, Hizni Salih, Kinga A Várnai, Harriet Branford-White, Liam Orrell, Andrew Osman, Kevin M Bradley, Lara Bonney, Daniel R McGowan, Jim Davies, Matthew S Prime, Andrew Bassim Hassan\",\"doi\":\"10.1017/pcm.2024.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the 'molecular tumour board' into 'standard of care' ensures a unified clinical decision pathway that both counteracts fragmentation and is the cornerstone of evidence-based delivery inside and outside of a research setting. Generally, integrated delivery has been restricted to specific (common) cancer types either within major cancer centres or small regional networks. Here, we focus on solutions in real-world integration of genomics, pathology, surgery, oncological treatments, data from clinical source systems and analysis of whole-body imaging as digital data that can facilitate cost-effectiveness analysis, clinical trial recruitment, and outcome assessment. This urgent imperative for cancer also extends across the early diagnosis and adjuvant treatment interventions, individualised cancer vaccines, immune cell therapies, personalised synthetic lethal therapeutics and cancer screening and prevention. Oncology care systems worldwide require proactive step-changes in solutions that include inter-operative digital working that can solve patient centred challenges to ensure inclusive, quality, sustainable, fair and cost-effective adoption and efficient delivery. Here we highlight workforce, technical, clinical, regulatory and economic challenges that prevent the implementation of precision oncology at scale, and offer a systematic roadmap of integrated solutions for standard of care based on minimal essential digital tools. These include unified decision support tools, quality control, data flows within an ethical and legal data framework, training and certification, monitoring and feedback. Bridging the technical, operational, regulatory and economic gaps demands the joint actions from public and industry stakeholders across national and global boundaries.</p>\",\"PeriodicalId\":72491,\"journal\":{\"name\":\"Cambridge prisms, Precision medicine\",\"volume\":\"2 \",\"pages\":\"e4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062796/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cambridge prisms, Precision medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/pcm.2024.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cambridge prisms, Precision medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/pcm.2024.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

尽管在基于基因组学的可操作变异识别方面取得了技术进步,而且药物开发也越来越关注这些特定靶点,但个性化肿瘤治疗模式的实现仍然充满挑战。为了确保我们能继续保持协调一致的势头,改善所有癌症类型的治疗效果,需要解决资金、技术和操作方面的障碍。例如,将 "分子肿瘤委员会 "完全整合并认证为 "标准治疗",可确保统一的临床决策路径,既能抵消碎片化,又是在研究环境内外提供循证服务的基石。一般来说,综合治疗仅限于大型癌症中心或小型区域网络内的特定(常见)癌症类型。在此,我们将重点关注在现实世界中整合基因组学、病理学、外科手术、肿瘤治疗、临床源系统数据和全身成像分析等数字数据的解决方案,以促进成本效益分析、临床试验招募和结果评估。癌症的这一迫切需求还延伸到早期诊断和辅助治疗干预、个性化癌症疫苗、免疫细胞疗法、个性化合成致命疗法以及癌症筛查和预防。全球肿瘤治疗系统需要积极改变解决方案,其中包括能够解决以患者为中心的挑战的术间数字化工作,以确保包容性、高质量、可持续、公平和具有成本效益的采用和高效交付。在此,我们强调了阻碍精准肿瘤学大规模实施的劳动力、技术、临床、监管和经济方面的挑战,并基于最基本的数字工具,为标准护理提供了一个系统的综合解决方案路线图。其中包括统一的决策支持工具、质量控制、伦理和法律数据框架内的数据流、培训和认证、监测和反馈。要弥合技术、操作、监管和经济方面的差距,需要公共和行业利益相关者跨越国家和全球界限,采取联合行动。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm.

The personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the 'molecular tumour board' into 'standard of care' ensures a unified clinical decision pathway that both counteracts fragmentation and is the cornerstone of evidence-based delivery inside and outside of a research setting. Generally, integrated delivery has been restricted to specific (common) cancer types either within major cancer centres or small regional networks. Here, we focus on solutions in real-world integration of genomics, pathology, surgery, oncological treatments, data from clinical source systems and analysis of whole-body imaging as digital data that can facilitate cost-effectiveness analysis, clinical trial recruitment, and outcome assessment. This urgent imperative for cancer also extends across the early diagnosis and adjuvant treatment interventions, individualised cancer vaccines, immune cell therapies, personalised synthetic lethal therapeutics and cancer screening and prevention. Oncology care systems worldwide require proactive step-changes in solutions that include inter-operative digital working that can solve patient centred challenges to ensure inclusive, quality, sustainable, fair and cost-effective adoption and efficient delivery. Here we highlight workforce, technical, clinical, regulatory and economic challenges that prevent the implementation of precision oncology at scale, and offer a systematic roadmap of integrated solutions for standard of care based on minimal essential digital tools. These include unified decision support tools, quality control, data flows within an ethical and legal data framework, training and certification, monitoring and feedback. Bridging the technical, operational, regulatory and economic gaps demands the joint actions from public and industry stakeholders across national and global boundaries.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信